Evidence map›Paper›PMID 42368572›Full record

ArticleActa pharmaceutica Sinica. B2026

RAD51-targeting small molecule degrader sensitizes

Yanlin Jian, Yibo Gao, Tianyang Zhou, Shan Xu, Bin Wang, Yizeng Fan, Jian Ma, Yang Gao, Jing Liu, Bohan Ma and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yanlin JianDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yibo GaoDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Tianyang ZhouDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Shan XuDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Bin WangDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yizeng FanDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Jian MaDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Yang GaoDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Jing LiuDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Bohan MaDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Lei LiDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors though effective in patients with homologous recombination (HR)-deficient tumors, a large population of patients remain unresponsive, primarily due to either the absence of HR-related mutation or the restoration of HR functionality. RAD51, a critical protein in HR repair signaling that ensures precise DNA lesion repair, represents a promising therapeutic target. Inspired by the clinical success of PARP inhibitors in treating

Indexed as

BRCA2DegraderHomologous recombinationPARP inhibitorsProstate cancerRAD51ResistanceSynthetic lethality

Identifiers

PMID42368572
PMCPMC13304771

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.